HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings a
4 hours ago
- #HDAC inhibitor
- #biomarkers
- #breast cancer
- The SYSUCC-020 trial investigated tucidinostat, metronomic capecitabine, and endocrine therapy for HR-positive/HER2-negative advanced breast cancer after CDK4/6 inhibitor progression.
- The combination showed an objective response rate of 25.8%, median progression-free survival of 5.39 months, and was generally well-tolerated.
- Exploratory biomarker analyses linked baseline TP53 mutations and circulating tumor cell positivity to shorter progression-free survival.